Clinical Trials

Date: 2015-09-25

Type of information: Initiation of the trial

phase: 3

Announcement: initiation of the trial

Company: Merck&Co (USA - NJ)

Product: pembrolizumab (MK-3475)

Action mechanism:

• monoclonal antibody/immune checkpoint inhibitor. Keytruda® (pembrolizumab - MK-3475) is an highly selective monoclonal anti-PD-1 antibody designed to restore the natural ability of the immune system to recognize and target cancer cells by selectively achieving dual ligand blockade (PD-L1 and PD-L2) of the PD-1 protein. By blocking PD-1, MK-3475 enables activation of the immune system’s T-cells that target cancer by essentially releasing a brake on the immune system. MK-3475 is currently being studied in three clinical trials for advanced melanoma including a Phase III trial of MK-3475 versus ipilimumab in ipilimumab-naïve advanced melanoma patients (PN 006). Enrollment is complete in the advanced melanoma cohorts in the company’s Phase IB trial (PN 001) and the Phase II trial (PN 002) comparing two doses of MK-3475 versus chemotherapy in patients with advanced melanoma who have progressed after prior therapy. Pembrolizumab is being evaluated across more than 30 types of cancers, as monotherapy and in combination. It is anticipated that by the end of 2014, the pembrolizumab development program will grow to more than 24 clinical trials, enrolling an estimated 6,000 patients at nearly 300 clinical trial sites worldwide. In April 2013, MK-3475 has received a Breakthrough Therapy designation for advanced melanoma from the FDA. In October 2014, the FDA has gralso anted Breakthrough Therapy Designation to Keytruda® (pembrolizumab) for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small cell lung cancer (NSCLC) whose disease has progressed on or following platinum-based chemotherapy. In November 2015, the FDA has granted Breakthrough Therapy Designation to Keytruda® for the treatment of patients with microsatellite instability high (MSI-H) metastatic colorectal cancer.

 

Disease: oesophageal carcinoma, oesophagogastric junction carcinoma

Therapeutic area: Cancer - Oncology

Country: Australia, Brazil, Canada, Czech Republic, Denmark, Estonia, Finland, France, Germany, Hong Kong, Israel, Italy, Japan, Republic of Korea, Malaysia, Norway, Peru, Portugal, Russian Federation, Singapore, Spain, Sweden, Taiwan, Turkey, UK, USA

Trial details:

• In the KEYNOTE-181 study, participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that has progressed after first-line standard therapy will be randomized to receive either single agent pembrolizumab or the Investigator's choice of standard therapy with paclitaxel, docetaxel, or irinotecan. The primary study hypothesis is that treatment with pembrolizumab will prolong progression-free survival (PFS) and/or overall survival (OS) as compared to treatment with standard therapy. (NCT02564263)

Latest news:

• • On September 29, 2015, a Phase 3 trial sponsored by Merck&Co was published on the NIH website ClinicalTrials.gov for pembrolizumab and is currently recruiting participants.

Is general: Yes